novo-nordisk-stock-plummets-after-new-weight-loss-drug-falls-short-against-rival
Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival

Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival

By Mary Prenon
1 Min Read
Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival

The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty Images

Stock prices for Denmark-based Novo Nordisk dropped by more than 15 percent on Feb. 23 after the global healthcare firm announced disappointing results from a clinical trial of CagriSema.

Known for its Ozempic injectable medication for treating diabetes and obesity, Novo Nordisk’s newest pharmaceutical just completed its phase 3 trial, called REDEFINE 4, an 84-week trial test of CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg injectable.

EU Opens New Investigation Into X Over Grok
How Social Media Is Warping People’s Relationship With Violence
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
3 Principles to Invest By, Whatever Comes Next
Peruvian Government Denies Alleged Appropriation of Colombian Territory
TAGGED:
Share This Article

You Might Also Like